Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3002)	6/23/2020 7:47:57 PM
From: Felix B	Read Replies (2) \| Respond to of 3557

What are the pricing implications with the government/BARDA funding all these Covid19 treatments? Surely there must be some restrictions on pricing?

To: Miljenko Zuanic who wrote (3002)	6/24/2020 8:27:16 AM
From: Biotechwantabe	Read Replies (2) \| Respond to of 3557

Will there be one price for prophylactic and separate for treatment. I thought the said 100sk for prophylactic but 10sk for treatment production. Not sure if it’s more doses or higher concentration ; maybe both. I Assume price will be dependent on how well it works for treatment. “Based on clinical trial data”. Give Barda discount for supporting r&d Make other countries pay full price; if there’s anything available.